Type 2 Pulmonary Hypertension Management

Core Management Principle

The European Society of Cardiology recommends optimal treatment of the underlying left heart disease using guideline-directed medical therapy for heart failure, as the primary management strategy for Type 2 pulmonary hypertension (PH-LHD) 1, 2
The cornerstone of therapy is addressing the left heart pathology that drives elevated pulmonary pressures, which directly targets the root cause: passive backward transmission of elevated left-sided filling pressures that increases right ventricular afterload 1, 2, 3

Diuretics are recommended to reduce left-sided filling pressures and pulmonary congestion in patients with PH-LHD 1, 2, 3
ACE inhibitors or ARBs are recommended for afterload reduction in patients with PH-LHD 1, 2
Beta-adrenoceptor blockers are recommended when indicated for the underlying heart failure in patients with PH-LHD 1, 2
SGLT2 inhibitors have demonstrated benefit in HFpEF and can improve pulmonary pressures in patients with PH-LHD 4
Sacubitril/valsartan (ARNI) is recommended for appropriate heart failure phenotypes in patients with PH-LHD 4
Mineralocorticoid receptor antagonists are recommended as part of guideline-directed therapy for patients with PH-LHD 4

Valvular surgery is recommended for significant valvular disease in patients with PH-LHD, with sustained PH reduction expected in weeks to months post-mitral valve surgery 1, 2
Cardiac resynchronization therapy is recommended for eligible patients with PH-LHD 1, 2
LV assist device implantation is recommended in advanced cases of PH-LHD 1, 2
Heart transplantation is recommended for end-stage disease in patients with PH-LHD 1, 2

The European Society of Cardiology recommends against the use of PAH-specific drug therapy (endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase-5 inhibitors) in PH-LHD, as it is a Class III recommendation (harm) 1, 2, 5, 6, 7

Doppler echocardiography can estimate elevated left-sided filling pressures in patients with PH-LHD, with a Class IIb recommendation 1, 5, 6, 7
Right heart catheterization may be required to confirm diagnosis, particularly when echocardiographic signs suggest severe PH or when distinguishing from PAH 1, 5, 6, 7

The European Respiratory Society notes that misdiagnosing PH-LHD as PAH and initiating PAH-specific therapy is a critical error that can lead to patient harm 8